CN111066918A - 一种降尿酸的健康茶及在制备治疗痛风药物中的应用 - Google Patents
一种降尿酸的健康茶及在制备治疗痛风药物中的应用 Download PDFInfo
- Publication number
- CN111066918A CN111066918A CN202010030427.1A CN202010030427A CN111066918A CN 111066918 A CN111066918 A CN 111066918A CN 202010030427 A CN202010030427 A CN 202010030427A CN 111066918 A CN111066918 A CN 111066918A
- Authority
- CN
- China
- Prior art keywords
- tea
- uric acid
- health tea
- gout
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 43
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229940116269 uric acid Drugs 0.000 title claims abstract description 40
- 201000005569 Gout Diseases 0.000 title claims abstract description 37
- 230000036541 health Effects 0.000 title claims abstract description 25
- 230000001603 reducing effect Effects 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 241001122767 Theaceae Species 0.000 title 2
- 244000269722 Thea sinensis Species 0.000 claims abstract description 51
- 235000013616 tea Nutrition 0.000 claims abstract description 43
- 230000035622 drinking Effects 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 8
- 235000009569 green tea Nutrition 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 7
- 244000197580 Poria cocos Species 0.000 claims abstract description 6
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 241000414067 Inonotus obliquus Species 0.000 claims abstract description 5
- 240000000249 Morus alba Species 0.000 claims abstract description 5
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 5
- 238000004806 packaging method and process Methods 0.000 claims abstract description 5
- 238000010298 pulverizing process Methods 0.000 claims abstract description 4
- 241000405414 Rehmannia Species 0.000 claims description 4
- 229930195210 Ophiopogon Natural products 0.000 claims 1
- 244000248557 Ophiopogon japonicus Species 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 16
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 15
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 10
- 229960003459 allopurinol Drugs 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 229960001338 colchicine Drugs 0.000 description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229960001193 diclofenac sodium Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 230000007937 eating Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical class OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010018641 Gouty tophus Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Polymers & Plastics (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种降尿酸的健康茶及在制备治疗痛风药物中的应用,其特征是健康茶的配方以质量计:绿茶50%,茯苓10%,桦树茸10%,熟地10%,麦冬10%,西洋參10%。其配制方法是将绿茶,茯苓,桦树茸,熟地,麦冬,西洋參粉碎成粗粉,混合均匀,桑皮纸小袋包装,每袋2克。该健康茶在制备治疗痛风药物中的应用,患者每次用1袋,一日一次,用水150毫升煎开5分钟后,凉至合适温度饮用。试验及临床结果表明,该健康茶能快速缓解痛风发作症状,有效降低患者血尿酸水平,较好地维持痛风缓解效果。
Description
技术领域
本发明属保健食品领域,更具体是一种降尿酸的健康茶及在制备治疗痛风药物中的应用。
背景技术
尿酸是人体内嘌呤的代谢产物,当体内血尿酸含量男性>420μmol/L,女性>360μmol/L时,就是高尿酸血症了。血尿酸浓度越高,痛风的发生风险就越大。我国大约有1.2亿高尿酸血症患者,约占总人口的10%。也就是说,你身边每10个人中,就可能有1位需要调节体内尿酸水平。尽管不是所有血尿酸偏高的人都会患痛风,但研究表明其中10%-15%的人会患病。
高尿酸血症会引起一系列系列疾病,如风湿,类风湿,痛风,尿结石,肾结石等,其中痛风是最常见的疾病,而且会给患者造成很大的痛苦。尽管对于痛风的病因和发病机制还不十分清楚,比较肯定的是高尿酸血症是痛风最重要的生化基础,由于血尿酸水平过高,导致尿酸结晶沉积在关节内而引发的,导致关节内和关节周围出现疼痛性炎症发作。大部分患者是尿酸排泄障碍,约10%患者因尿酸生成过多导致,还有因嘌呤代谢相关酶缺陷而导致代谢障碍。
流行病学资料表明,痛风见于世界各国,受地域,民族,饮食习惯影响。目前我国痛风患病率为1%--3%,随着人民寿命的延长,饮食生活方式的改变,这一数据呈逐年上升趋势。抗痛风药销售额增长率几乎每年都保持在30%以上,可见痛风发病人群之多。
目前对于痛风的治疗分为急性期治疗,间歇期和慢性期治疗。
痛风急性发作期需及早(24小时内)进行抗炎止痛治疗,临床使用非甾体类消炎药,秋水仙碱和糖皮质激素,以提高患者生活质量。但在痛风急性发作症状缓解后应继续治疗,以防症状再次出现。
间歇期和慢性期治疗:对痛风急性发作症状缓解后患者,急性痛风关节炎频繁发作(大于每年2次)者,有慢性痛风关节炎或痛风石患者,应行降尿酸治疗,将患者血尿酸水平控制在适当水平,有助于缓解症状,控制病情。痛风患者在进行降尿酸治疗时应參考高尿酸血症的机制采用个性化用药方案,抑制尿酸生成使用别嘌呤醇或非布司他,促进尿酸排泄使用苯溴马隆,丙磺舒等。
然而,这些治疗药物都具有一定的不良反应,如胃肠道症状,皮疹,对肝功能影响,对肾脏影响,有一些还很严重。
经中国专利检索,用于痛风治疗的中药专利申请有700多件;民间应用玉米须单用或配合其他药物用于治疗或预防痛风,但一般需使用较长时间,才有效果。
发明内容
针对上述不足,临床需要更好的治疗药物和方法。
为此本发明提供一种降尿酸的健康茶及在制备治疗痛风药物中的应用。本发明要解决的技术问题是提供一种降低尿酸的健康茶,可以快速缓解痛风急性发作症状,抑制嘌呤氧化酶活性,减少尿酸的产生,调节机体酸碱平衡,促进尿酸排泄,降低血尿酸水平。
本发明是通过以下技术方案实现上述目的。
一种降尿酸的健康茶,其特征是它的配方以质量计:绿茶 50% 茯苓 10% 桦树茸10% 熟地 10% 麦冬 10% 西洋參 10%。
一种降尿酸的健康茶的配制方法,将绿茶,茯苓,桦树茸,熟地,麦冬,西洋參粉碎成粗粉,混合均匀,桑皮纸小袋包装,每袋2克。
一种降尿酸的健康茶及在制备治疗痛风药物中的应用,其特征在于患者每次1袋,每日一次,用水150毫升煎开5分钟后,凉至合适温度饮用。
本发明的一种降尿酸健康茶能快速缓解痛风急性发作症状,抗炎止痛,并能较好地稳定缓解效果;同时,继续使用具有良好的降尿酸作用。
为此我们进行了一种降尿酸健康茶的治疗作用研究。
1.初步毒性和安全性试验:
选择健康的ICR小鼠20只,雄雌各半,体重18-22g,给药前动物禁食约12小时,健康茶粗粉粉碎成细粉,用羧甲基纤维素钠配制成混悬液,按最大浓度0.4g/mL、最大体积40mL/kg体重灌胃给药,于上午8时和下午3时分别按上述剂量灌胃一次,给药后连续观察14天,记录动物中毒和死亡情况。灌胃给药后,动物未出现明显的异常反应,14天连续观察,未见动物出现任何中毒反应,活动自如,进食饮水和大小便均正常,体重正常增长,一般情况良好;20只动物无一死亡,处死动物后尸检,各脏器未见肉眼可见的病理改变,未测得健康茶小鼠灌胃给药的最大耐受量,毒性远远小于别嘌呤醇(LD50=700mg/kg).
选择健康的ICR小鼠20只,雄雌各半,体重18-22g,给药前动物禁食约12小时,健康茶煎煮后过滤,滤液浓缩至含生药0.4g/mL,按40mL/kg(折合相当于人体正常给药量的480倍)体重灌胃给药一次,给药后连续观察14天,记录动物中毒和死亡情况。灌胃给药后,动物未出现明显的异常反应,14天连续观察,未见动物出现任何中毒反应,活动自如,进食饮水和大小便均正常,体重正常增长,一般情况良好;20只动物无一死亡,处死动物后尸检,各脏器未见肉眼可见的病理改变,未测得健康茶小鼠灌胃给药的最大耐受量,毒性远远小于别嘌呤醇(LD50=700mg/kg)。
2.降尿酸效果研究
为验证本发明的健康茶的降尿酸功效,进行了降低高尿酸血症对比试验研究:将雄性昆明小鼠分为数量相等6个组,每组10只,分别为对照组、模型组、别嘌呤醇组、治疗组高剂量组,中剂量组,低剂量组,其中,模型组、别嘌呤醇组、治疗组高,中,低剂量组均采用腹腔注射氧嗪酸钾盐法(300mg/kg一次性腹腔注射给药)进行高尿酸造模处理。别嘌呤醇组采用别嘌呤醇进行治疗,而治疗组采用健康茶进行治疗处理,两者均通过拌入饲料的方式进行,其中别嘌呤醇按40mg/kg拌入饲料,而健康茶高中低剂量组分别按1g/kg,0.5g/kg,0.2g/kg拌入饲料,对照组、模型组采用相同的饲料进行饲养,饲料中不掺入任何治疗药物,连续饲喂7天,观察各组小鼠血尿酸水平变化。
表1:各组小鼠实验末血尿酸浓度结果
组别 | 尿酸(mmol/L) | 组别 | 尿酸(mmol/L) |
对照组 | 78.5±3.6 | 治疗高剂量组 | 168.7±8.6 |
模型组 | 310.4±11.3 | 治疗中剂量组 | 176.2±6.9 |
别嘌呤醇组 | 213.7±12.4 | 治疗低剂量组 | 193.5±11.2 |
试验结果表明,别嘌呤醇组,治疗高剂量组,治疗中剂量组和治疗低剂量组与模型组比较,效果明显(ρ<0.01);而治疗高中低剂量组与别嘌呤醇组比较,效果优于后者,其中,治疗高,中剂量组与别嘌呤醇组比较(ρ<0.05)具统计学意义,而治疗低剂量组与别嘌呤醇组比较(ρ>0.05),不具统计学意义。
本发明的一种降尿酸的健康茶能快速缓解痛风发作症状,止痛消炎的机制我们还不十分清楚,但实际应用中饮用一次可减轻症状,饮用2次可完全缓解;持续饮用一周,一月内未见复发。因积累的长期患者不多,所以对长期患者的长效未有统计。
下面通过实施例对本发明技术方案作进一步说明。但本发明不限于所描述的实施方式。对于本领域的技术人员而言,在不脱离本发明原理和精神的情况下,对这些实施方式进行多种变化、修改、替换和变型,仍落入本发明的保护范围内。
实施例1:一种降尿酸的健康茶的制备
按配方称取绿茶100克,茯苓20克,桦树茸20克,熟地20克,麦冬20克,西洋參20克,粉碎成粗粉,混合均匀,桑皮纸小袋包装,每袋2克,即得。使用时一袋加水150毫升,煎开5分钟后,凉至40-50℃饮用。
实施例2:一种降尿酸的健康茶的制备
按配方称取绿茶200克,茯苓40克,桦树茸40克,熟地40克,麦冬40克,西洋參40克,粉碎成粗粉,混合均匀,桑皮纸小袋包装,每袋2克,即得。使用时一袋加水150毫升,煎开5分钟后,凉至室温饮用。
实施例3:治疗效果
张艳,女,47岁,住湖北省洪湖市新滩镇,2018年6月痛风病发作,肿疼痛难忍,服双氯芬酸钠或布洛芬缓释胶囊和秋水仙碱片,输液加地噻米松等。三到五天症状完全缓解,但一周后复发。后改用喝健康茶二天,症状完全缓解。服用方法是每天晚上用二克健康茶加一百五十毫升水煎开五分钟后,凉到适合温度服用。回访,一月内未复发。
实施例4:治疗效果
许正西,男,50岁,住湖北省洪湖市新滩镇,2019年2月痛风急性发作,疼痛难忍,服双氯芬酸钠或布洛芬缓释胶囊,秋水仙碱片,输液加地噻米松等。三到五天症状完全缓解,10天后复发。如此反复,难以忍受。后改服健康茶,每天晚上用2克健康茶加150毫升水煎开5分钟后,凉到适合温度服用,二天症状完全缓解。继续服用一周巩固疗效,回访,二月内未复发。
实施例5:治疗效果
游志斌,男,55岁,住湖北省武汉市,2019年5月痛风发作,疼痛难忍,服双氯芬酸钠或布洛芬缓释胶囊及秋水仙碱片,输液加地噻米松等。三到五天症状完全缓解。一月内复发3次,痛苦不堪。经人介绍改服健康茶二天治愈。每天晚上用2克健康茶加150毫升水煎开5分钟后,凉到适合温度服用,继续服用一周巩固疗效,回访,二月内未复发。
实施例6:治疗效果
许先生,男,63岁,住湖北省武汉市东西湖区,2019年6月痛风急性发作,疼痛难忍,服双氯芬酸钠或布洛芬缓释胶囊及秋水仙碱片,输液消炎加地噻米松等,民间偏方用过车前草煎水泡茶无效。医院治疗三到五天才能症状完全缓解。每年至少复发3-5次。经人介绍改服健康茶二天症状完全缓解。每天晚上用二克健康茶加一百五十毫升水煎开五分钟后,凉到适合温度服用,继续服用一周巩固疗效,回访,3月内未复发。
Claims (3)
1.一种降尿酸的健康茶,其特征是它的配方以质量计:绿茶50% 茯苓10% 桦树茸10% 熟地10% 麦冬10% 西洋参10%。
2.根据权利要求1的一种降尿酸的健康茶,其特征在于其配制方法是,将绿茶,茯苓,桦树茸,熟地,麦冬,西洋参粉碎成粗粉,混合均匀,桑皮纸小袋包装,每袋2克。
3.根据权利要求1的一种降尿酸的健康茶,其特征在于在制备治疗痛风药物中的应用,患者每次1袋,每日一次,用水150毫升煎开5分钟后,凉至合适温度饮用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010030427.1A CN111066918A (zh) | 2020-01-13 | 2020-01-13 | 一种降尿酸的健康茶及在制备治疗痛风药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010030427.1A CN111066918A (zh) | 2020-01-13 | 2020-01-13 | 一种降尿酸的健康茶及在制备治疗痛风药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111066918A true CN111066918A (zh) | 2020-04-28 |
Family
ID=70322948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010030427.1A Pending CN111066918A (zh) | 2020-01-13 | 2020-01-13 | 一种降尿酸的健康茶及在制备治疗痛风药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111066918A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113952411A (zh) * | 2021-11-09 | 2022-01-21 | 贵州中医药大学第二附属医院 | 一种治疗高尿酸的袋泡茶、制备方法及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106902187A (zh) * | 2017-01-23 | 2017-06-30 | 武汉玉竹科技有限公司 | 一种预防和治疗痛风的袋泡茶 |
CN107496762A (zh) * | 2017-09-20 | 2017-12-22 | 贵阳健圣堂药材有限公司 | 一种降低高尿酸预防改善痛风的保健茶及其制备方法和应用 |
-
2020
- 2020-01-13 CN CN202010030427.1A patent/CN111066918A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106902187A (zh) * | 2017-01-23 | 2017-06-30 | 武汉玉竹科技有限公司 | 一种预防和治疗痛风的袋泡茶 |
CN107496762A (zh) * | 2017-09-20 | 2017-12-22 | 贵阳健圣堂药材有限公司 | 一种降低高尿酸预防改善痛风的保健茶及其制备方法和应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113952411A (zh) * | 2021-11-09 | 2022-01-21 | 贵州中医药大学第二附属医院 | 一种治疗高尿酸的袋泡茶、制备方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN102935116A (zh) | 一种具有降血糖功效的药物组合物或保健品 | |
CN103446525A (zh) | 治疗皮肤病的中药组合物及其制备方法和应用 | |
CN111066918A (zh) | 一种降尿酸的健康茶及在制备治疗痛风药物中的应用 | |
CN104352624B (zh) | 蒙药芯芭正丁醇提取物在制备防治糖尿病药物中的应用 | |
CN104042720A (zh) | 具有防治糖尿病并发抑郁症的中药及其应用 | |
CN101966312B (zh) | 一种治疗慢性肾衰竭的中药组合物的制备方法 | |
CN103735761B (zh) | 一种防治阿尔茨海默病的药物组合物及其制备方法 | |
CN107778340A (zh) | (20S,24R)‑20,24‑环氧达玛烷‑3β,12β,25‑三醇及其应用 | |
CN100528186C (zh) | 一种治疗慢性肾功能衰竭中药复方注射剂的制备工艺以及应用 | |
CN103169917A (zh) | 一种治疗精神抑郁症的中药组合物及其制备方法 | |
CN103735630B (zh) | 一种治疗痛风的中药 | |
CN102805799A (zh) | 一种具有抗恶性肿瘤功效的中药组合物 | |
CN103705812B (zh) | 一种治疗痛风的药物组合物及其制备方法和用途 | |
CN101549032B (zh) | 具有抗肺癌作用的药物组合物及其在制备抗肺癌药物中的应用 | |
CN114246910A (zh) | 一种治疗痛风的中药组合物及其用途 | |
CN101396437B (zh) | 一种中药抗痛风滴丸 | |
CN100462094C (zh) | 一种治疗泌尿系统疾病的中药制剂 | |
CN103719661A (zh) | 补血口服液保健品 | |
JP2014155489A (ja) | サルトリイバラ葉抽出物を含有する糖尿予防及び治療用の組成物 | |
AU2020103240A4 (en) | A Chinese herbal medicine composition, a pharmaceutical preparation and the preparation method thereof | |
CN110693936B (zh) | 用于降低尿酸、防治高尿酸血症或痛风的中药组合物及用途 | |
CN101810782B (zh) | 一种治疗糖尿病的药物 | |
CN106389439A (zh) | 一种治疗肝硬化腹水的中西药组合及其制备方法和应用 | |
CN117919316A (zh) | 针对前列腺癌的多靶点全因中药复方组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200428 |
|
RJ01 | Rejection of invention patent application after publication |